Healthcare-focused SPAC Blue Water Acquisition IV prices $125 million IPO
IPO Overview
Blue Water Acquisition IV, a fourth blank check company led by the founder of Blue Water Venture Partners targeting healthcare and tech, raised $125 million by offering 12.5 million units at $10. Each unit consists of one share of common stock and one-half of one warrant, exercisable at $11.50.
Blue Water Acquisition IV is led by CEO and Chairman Joseph Hernandez, the founder and Senior Managing Partner of investment firm Blue Water Venture Partners, and the founder of 2022 biotech IPO Blue Water Vaccines （now Onconetix; ONCO）。 The SPAC plans to target the biotechnology, healthcare, and technology sectors. Particular areas of interest include pharmaceuticals, medical devices, telemedicine, AI/ML, and cloud computing, among others.
Management has led various SPACs, most recently Blue Water Acquisition III （BLUWU; +5% from offer price）， which made headlines for its submission of an unsolicited bid to acquire Citgo Petroleum parent PDV Holding this past September, before it later suspended that bid in November. Blue Water Acquisition II （BWTRU） filed for a $75 million IPO in October 2021, but withdrew its filing the following August. The first Blue Water Acquisition merged with Clarus Therapeutics in 2021, a company that later filed for bankruptcy in 2022.
Blue Water Acquisition IV plans to list on the NYSE under the symbol BWIV.U. BTIG acted as sole bookrunner on the deal.
About the Company
We are a blank check company. While we may pursue an acquisition opportunity in any business, industry, sector or geographical location, we intend to focus on high-potential companies in the biotechnology, healthcare and technology sectors. Our mission is to leverage our management team’s extensive expertise and deep industry connections to drive transformative advancements and generate substantial returns for our investors. We are strategically positioned to capitalize on the immense opportunities within the biotechnology, healthcare, and technology sectors. With a seasoned team, extensive industry experience, and a disciplined investment approach, we are committed to creating value for our investors while fostering the next generation of industry leaders. The biotechnology and healthcare sectors are experiencing rapid growth fueled by innovations in drug discovery, personalized medicine, medical devices, and telemedicine. We intend to target companies that are leading the charge in developing groundbreaking therapies, diagnostic tools, and health technology solutions.
